Indian Journal of Science and Technology

Open Access Open Access  Restricted Access Subscription Access

Traditional Antidotes Kallunk Oxide in the Treatment of HIV/AIDS


Affiliations
1 Traditional Alternative Medicine Research Center TAMRC-INDIA, IPF Code: 10001796, Velumparambil House, Kakkazhom-PO, Alleppey, Kerala-688005, India
 

Immune deficiency is an important problem on HIV/AIDS patients. Traditional antidotes "Kallunk oxide", a Complementary and Alternative Medicine (CAM), could be better restored the immunity in initial stage of HIV type-1 patients. The performed modest phase-1 study was observational, prospective and designs as open label, case- only, randomized, treatment, and efficacy research enrolled with CD3+ and CD4+ T cell counts >450, >250 and 3 of 20 HIV/AIDS patients between the ages 8 and 55 years from both genders at the Project Site Office, HIRS, Palakkad- Dt, Kerala, India. The participants were received traditional antidotes "Kallunk oxide" treatment and the study includes Lymphocyte cell counts as assessed by Flow fluorescence cytometry analysis. The absolute CD3+ and CD4+ T cell numbers increased in four (4) HIV type-1 patients, as confirmed by the baseline CD4+ T cell counts above 450 cu/mm3, showing above 50% increase after the CAM therapy. This traditional antidotes "Kallunk oxide" treatment boosts initial stage of HIV type-1 patients' immunity.

Keywords

Aids, Antidote, Kallunk Oxide, HIV Treatment, Siddha Therapy, Traditional Indian Medicine
User

  • Cachay ER, Wyles DL, Goicoechea M, Torriani FJ, Ballard C, Colwell B, Gish RG and Mathews WC (2011) Reliability and predictive validity of a hepatitisrelated symptom inventory in HIV-infected individuals referred for Hepatitis C treatment. AIDS Res. & Therapy. 8, 29, (1-5).

  • David M Moore, Anna Awor, Robert S Downing, Willy Were, Peter Solberg, David Tu, Keith Chan, Robert S Hogg and Jonathan Mermin (2007) Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index. AIDS. Res. Therapy. 4, 1, (1-6).

  • Fiscus SA, Kovacs A, Petch LA, Hu C, Wiznia AA, Mafioso LM, Yogev R, McIntosh K, Pelton SI, Napravnik S, Stanley K and Nachman SA (2007) Baseline resistance to nucleoside reverse transcriptase inhibitors fails to predict virologic response to combination therapy in children (PACTG 338). AIDS. Res. Therapy. 4, 2, (1-6).

  • Goldrosen MH and Straus SE (2004) Complementary and alternative medicine: assessing the evidence for immunological benefits, (1-1).

  • Gogtay NJ, Bhatt HA, Dalvi SS and Kshirsagar NA (2002) The use and safety of non-allopathic Indian medicines. Drug Saf. 25-14, (1-1).

  • Gupta S, Mathur P, Maskey D, Wig N and Singh S (2007) Immune restoration syndrome with disseminated penicillium marneffei and Cytomegalovirus co-infections in an AIDS patient, AIDS. Res. Therapy. 4, 21, (1-4).

  • Jeannie S Huang, Shawn Harrity, Daniel Lee, Karen Becerra, Rosanne Santos, W Christopher Mathews (2006) Body image in women with HIV: a cross-sectional evaluation. AIDS. Res. Therapy. 3, 17, (1-6).

  • Kumar A, Kilaru KR, Sandiford S and Forte S (2006) Trends in the HIV related hospital admissions in the HAART era in Barbados. AIDS. Res. Therapy. 4, 4, (1- 5).

  • Lichtenstein K, Balasubramanyam A, Sekhar R and Freedland E (2007) HIV-associated adipose redistribution syndrome (HARS): definition, epidemiology and clinical impact. AIDS. Res. Therapy. 4, 16, (1-3).

  • Mutimura E, Stewart A and Crowther NJ (2007) Assessment of quality of life in HAART-treated HIVpositive subjects with body fat redistribution in Rwanda. AIDS. Res. Therapy. 4, 19, (1-5).

  • Malhotra A, Gaur S, Whitley-Williams P, Loomis C and Petrova A (2007) Protease inhibitor associated mutations compromise the efficacy of therapy in human immunodeficiency virus 1 (HIV-1) infected pediatric patients: a cross-sectional study. AIDS. Res. Therapy. 4, 15, (1-5).

  • Morris JD, Golub ET, Mehta SH, Jacobson LP and Gange SJ (2007) Injection drug use and patterns of highly active antiretroviral therapy use: an analysis of ALIVE, WIHS, and MACS cohorts. AIDS. Res. Therapy. 4, 12, ((1-5).

  • Manosuthi W, Chimsuntorn S, Likanonsakul S and Sungkanuparph S (2007) Safety and efficacy of a generic fixed-dose combination of stavudine, lamivudine and nevirapine antiretroviral therapy between HIV-infected patients with baseline CD4 <50 versus CD4 ≥ 50 cells/mm3 . AIDS. Res. Therapy. 4(6) (1-4).

  • Fritts M, Crawford CC, Quibell D, Gupta A, Jonas WB, Coulter I and SA Andrade (2008) Traditional indian medicine and homeopathy for HIV/AIDS: a review of the literature. AIDS. Res. Therapy. 5 (25) (1-6).

  • Moore DM, Awor A, Downing RS, Were W, Solberg P, Tu D, Chan K, Hogg RS and Mermin J (2007) Determining eligibility for antiretroviral therapy in resource-limited settings using total lymphocyte counts, hemoglobin and body mass index. AIDS. Res. Therapy. 4 (1), (1-4).

  • Patrick S Sullivan, Maxine Denniston, Ad McNaghten, Susan E Buskin, Stephanie T Broyles and Eve D Mokotoff (2007) Use of a population-based survey to determine incidence of AIDS-defining opportunistic illnesses among HIV-positive persons receivingmedical care in the United States. AIDS. Res. Therapy. 4 (17), (1-6).

  • Preeyaporn Srasuebkul, Alexandra Calmy, Jialun Zhou, Nagalingeswaran Kumarasamy, Matthew Law and Poh Lian Lim (2007) Impact of drug classes and treatment availability on the rate of antiretroviral treatment change in the TREAT Asia HIV Observational Database (TAHOD). AIDS. Res. Therapy. 4(18), (1-5).

  • Paskaleva EE, Lin X, Li W, Cotter R, Klein MT, Roberge E, Yu EK, Clark B, Veille JC, Liu Y, Lee DYW and Canki M (2006) Inhibition of highly productive HIV-1 infection in T cells, primary human macrophages, microglia, and astrocytes by Sargassum fusiforme. AIDS. Res. Therapy. 3 (15), (1-4).

  • Ramjee G, Morar NS, Braunstein S, Friedland B, Jones H and van de Wijgert J (2007) Acceptability of carraguard, a candidate microbicide and methyl cellulose placebo vaginal gels among HIV-positive women and men in Durban, South Africa. AIDS. Res. Therapy. 4 (20), (1-6).

  • Ramjee G, Morar NS, Mtimkulu J, Mantell JE and Gharbaharan V (2007) Perceptions of vaginal microbicides as an HIV prevention method among health care providers in KwaZulu-Natal, South Africa. AIDS. Res. Therapy. 4(7), (1-9).

  • Simone E Langford, jintanat Ananworanich and David A Cooper (2007) Predictors of disease progression in HIV infection: a review. AIDS. Res. Therapy. 4(11), (1-12).

  • Smita J, Soma D, Beverly B, Albert P, Jo Ann K, Fang G, Missy C, Lydia ST, Anjali P, Arun R, Sanjay M and Steven JR (2006) The HIV Prevention Trial Network (HPTN) 047 Protocol Team: Phase I safety study of 0.5% PRO 2000 vaginal Gel among HIV un-infected women in Pune, India. AIDS. Res. Therapy. 3(4), (1-4).

  • Thakar MR, Kumar BK, Mahajan BA, Mehendale SM and Paranjape RS (2006) Comparison of capillary based microflurometric assay for CD4+ T cell count estimation with dual platform Flow cytometry. AIDS. Res. Therapy. 3(26), (1-6).

  • Vidal JE, Fink MC, Cedeno-Laurent F, Delbue S, Ferrante P, Dauar RF, Filho FB, Nogueira RS, Calore EE, Pannuti CS, Trujillo JR and de Oliveira ACP (2007) BK virus associated meningoencephalitis in an AIDS patient treated with HAART. AIDS. Res. Therapy. 4(13), (1-6).

  • Wilson ME, Allred KF, Kordik EM, Jasper DK, Rosewell AN and Bisotti AJ (2007) Gender-specific effects of HIV protease inhibitors on body mass in mice. AIDS. Res. Therapy. 4(8), (1-8).

  • Yasmin pirzada, Sadik Khuder and Haig Donabedian (2006) Predicting AIDS – related events using CD4 percentage or CD4 absolute counts. AIDS. Res. Therapy. 3(20), (1-7).


Abstract Views: 362

PDF Views: 109




  • Traditional Antidotes Kallunk Oxide in the Treatment of HIV/AIDS

Abstract Views: 362  |  PDF Views: 109

Authors

Ramakrishnan Madhusoodanan
Traditional Alternative Medicine Research Center TAMRC-INDIA, IPF Code: 10001796, Velumparambil House, Kakkazhom-PO, Alleppey, Kerala-688005, India

Abstract


Immune deficiency is an important problem on HIV/AIDS patients. Traditional antidotes "Kallunk oxide", a Complementary and Alternative Medicine (CAM), could be better restored the immunity in initial stage of HIV type-1 patients. The performed modest phase-1 study was observational, prospective and designs as open label, case- only, randomized, treatment, and efficacy research enrolled with CD3+ and CD4+ T cell counts >450, >250 and 3 of 20 HIV/AIDS patients between the ages 8 and 55 years from both genders at the Project Site Office, HIRS, Palakkad- Dt, Kerala, India. The participants were received traditional antidotes "Kallunk oxide" treatment and the study includes Lymphocyte cell counts as assessed by Flow fluorescence cytometry analysis. The absolute CD3+ and CD4+ T cell numbers increased in four (4) HIV type-1 patients, as confirmed by the baseline CD4+ T cell counts above 450 cu/mm3, showing above 50% increase after the CAM therapy. This traditional antidotes "Kallunk oxide" treatment boosts initial stage of HIV type-1 patients' immunity.

Keywords


Aids, Antidote, Kallunk Oxide, HIV Treatment, Siddha Therapy, Traditional Indian Medicine

References





DOI: https://doi.org/10.17485/ijst%2F2011%2Fv4i12%2F30310